MT Newswires
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise
➖
AI Sentiment
Neutral
5/10
- Home
- ONCY
as of 12-18-2025 3:31pm EST
$1.00
$0.01
-0.99%
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Chart Type:
Time Range:
| Founded: | 1998 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 106.1M | IPO Year: | 1999 |
| Target Price: | $6.00 | AVG Volume (30 days): | 683.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $1.51 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ONCY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 73.86%
73.86%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Oncolytics Biotech Inc. News
ONCY Breaking Stock News: Dive into ONCY Ticker-Specific Updates for Smart Investing
Business Wire
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
📈
AI Sentiment
Highly Positive
9/10
Compare ONCY vs Leading Stocks
See how ONCY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ONCY Oncolytics Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.